Video Guided School Based Treatment of Youth Depression

描述（由申请人提供）：青年抑郁症是一种严重的，损害性的条件。青春期后其发病率急剧上升，突出了青春期早期治疗的公共卫生意义。我们的长期目标是开发和完善青年抑郁症的治疗方法，这种方法在各种青年环境中有效且可部署。在这里，我们专注于证据表明大多数青少年心理健康护理发生的环境：学校。努力传播经验支持的认知行为疗法（CBT）到学校还没有很成功的日期，也许至少有两个原因：（a）大多数CBT程序的设计可能有有限的用户吸引力，（B）CBT程序没有被证明优于目前的学校为基础的干预措施，所以没有一个令人信服的逻辑情况下改变。在本申请中，我们解决了这两个潜在的问题。 为了解决用户的上诉问题，我们已经从文献中的鲁棒设计，以重组我们自己的CBT计划-初级和二级控制增强训练（PASCET）作为视频引导治疗。为了解决改变问题的情况下，我们提出了一个试验，我们的视频引导治疗与常用的学校为基础的治疗方法作为比较条件。在试验中，符合抑郁症诊断标准的六年级和七年级学生将被随机分配到两种情况下，组形式和治疗剂量相匹配，所有治疗将在中学进行。将在治疗后和1年随访时评估抑郁和其他结局。

DESCRIPTION (provided by applicant): Youth depression is a serious, impairing condition. Its prevalence increases sharply following puberty, highlighting the public health significance of treatment in early adolescence. Our long-term goal is to develop and refine treatment for youth depression that is effective and deployable in a variety of youth settings. Here we focus on the setting in which evidence suggests most youth mental health care occurs: the school. Efforts to disseminate empirically supported cognitive behavioral therapies (CBTs) to schools have not been very successful to date, perhaps for at least 2 reasons: (a) the design of most CBT programs may have limited user appeal, and (b) CBT programs have not been shown to outperform current school-based interventions, so there is not a compelling logical case for change. In this application, we address both potential problems. To address the user appeal issue, we have drawn from the literature on robust design to restructure our own CBT program--Primary and Secondary Control Enhancement Training (PASCET) as a video-guided treatment. To address the case for change issue, we propose a trial of our video-guided treatment with a commonly used school-based treatment approach as the comparison condition. In the trial, 6th and 7th graders who meet diagnostic criteria for depressive disorders will be randomly assigned to the two conditions, matched for group format and treatment dose, and all treatment will take place in middle schools. Depression and other outcomes will be assessed at post-treatment and a 1-year follow-up.